StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) stock

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$27.75−0.18 (-0.64%)

Close on Nov 17, 2026Market cap $1.81BP/E –Yield –

Zenas BioPharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Zenas BioPharma's profit margin for the twelve months ending Dec 31, 2025 was -3777.4%. For fiscal 2025 it was -3777.4%, against -3139.8% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-3777.4%−637.6
FY2024Dec 31, 2024-3139.8%−3065.5
FY2023Dec 31, 2023-74.2%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-1089.2%−1160.4
Q2 FY2026Jun 30, 2026-11145.6%–
Q1 FY2025Mar 31, 2025-335.7%–
Q4 FY2024Dec 31, 2024-1052.1%–
Q3 FY2023Sep 30, 202371.2%–

More Zenas BioPharma figures

See a number that looks wrong?